SEAFARER EXPLORATION CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SEAFARER EXPLORATION CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $16.3K | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | $19.2K | Apr 22, 2025 |
| FY2023 | Dec 31, 2022 | $13.0K | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $23.8K | Apr 17, 2023 |
| FY2022 | Dec 31, 2020 | $10.6K | Apr 18, 2022 |
| FY2020 | Dec 31, 2019 | $14.0K | Apr 12, 2021 |
| FY2011 | Dec 31, 2011 | $0 | Feb 1, 2013 |
| FY2011 | Dec 31, 2010 | $0 | Feb 1, 2013 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.74M) | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | ($3.90M) | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | ($3.18M) | Apr 22, 2025 |
| FY2023 | Dec 31, 2022 | ($2.62M) | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | ($2.63M) | Apr 17, 2023 |
| FY2022 | Dec 31, 2020 | ($2.66M) | Apr 18, 2022 |
| FY2020 | Dec 31, 2019 | ($2.31M) | Apr 12, 2021 |
| FY2019 | Dec 31, 2018 | ($1.28M) | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | ($999.8K) | Apr 22, 2019 |
| FY2017 | Dec 31, 2016 | ($1.35M) | Apr 11, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.55M) | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | ($3.34M) | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | ($3.05M) | Apr 22, 2025 |
| FY2023 | Dec 31, 2022 | ($2.43M) | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | ($2.35M) | Apr 17, 2023 |
| FY2022 | Dec 31, 2020 | ($2.70M) | Apr 18, 2022 |
| FY2020 | Dec 31, 2019 | ($2.05M) | Apr 12, 2021 |
| FY2019 | Dec 31, 2018 | ($1.05M) | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | ($733.2K) | Apr 22, 2019 |
| FY2017 | Dec 31, 2016 | ($674.9K) | Apr 11, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $574.8K | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | $490.2K | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | $325.2K | Apr 22, 2025 |
| FY2023 | Dec 31, 2022 | $172.9K | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $439.8K | Apr 17, 2023 |
| FY2022 | Dec 31, 2020 | $463.5K | Apr 18, 2022 |
| FY2020 | Dec 31, 2019 | $444.0K | Apr 12, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.02M) | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | ($2.87M) | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | ($2.31M) | Apr 22, 2025 |
| FY2023 | Dec 31, 2022 | ($1.99M) | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | ($1.72M) | Apr 17, 2023 |
| FY2022 | Dec 31, 2020 | ($1.89M) | Apr 18, 2022 |
| FY2020 | Dec 31, 2019 | ($1.65M) | Apr 12, 2021 |
| FY2019 | Dec 31, 2018 | ($504.1K) | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | ($637.6K) | Apr 22, 2019 |
| FY2017 | Dec 31, 2016 | ($370.1K) | Apr 11, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $58.4K | Apr 6, 2026 |
| FY2023 | Dec 31, 2022 | $145 | Apr 17, 2024 |
| FY2022 | Dec 31, 2020 | $12.0K | Apr 18, 2022 |
| FY2016 | Dec 31, 2015 | $1.0K | Apr 11, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $275.7K | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | $288.4K | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | $920.2K | Apr 22, 2025 |
| FY2023 | Dec 31, 2022 | $343.4K | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $289.0K | Apr 17, 2023 |
| FY2022 | Dec 31, 2020 | $550.0K | Apr 18, 2022 |
| FY2020 | Dec 31, 2019 | $1.06M | Apr 12, 2021 |
| FY2019 | Dec 31, 2018 | $80.8K | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | $115.9K | Apr 22, 2019 |
| FY2017 | Dec 31, 2016 | $100.2K | Apr 11, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.70M | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | $3.10M | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | $2.54M | Apr 22, 2025 |
| FY2023 | Dec 31, 2022 | $1.84M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $1.76M | Apr 17, 2023 |
| FY2022 | Dec 31, 2020 | $1.50M | Apr 18, 2022 |
| FY2020 | Dec 31, 2019 | $1.27M | Apr 12, 2021 |
| FY2019 | Dec 31, 2018 | $1.57M | Apr 3, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.43M) | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | ($2.81M) | Apr 6, 2026 |
| FY2025 | Dec 31, 2023 | ($1.62M) | Apr 6, 2026 |
| FY2024 | Dec 31, 2022 | ($1.50M) | Apr 22, 2025 |
| FY2023 | Dec 31, 2021 | ($1.48M) | Apr 17, 2024 |
| FY2022 | Dec 31, 2020 | ($947.0K) | Apr 17, 2023 |
| FY2022 | Dec 31, 2019 | ($206.5K) | Apr 18, 2022 |
| FY2020 | Dec 31, 2018 | ($1.49M) | Apr 12, 2021 |
| FY2019 | Dec 31, 2017 | ($1.11M) | Apr 3, 2020 |
| FY2018 | Dec 31, 2016 | ($972.7K) | Apr 22, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($34.99M) | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | ($32.24M) | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | ($28.35M) | Apr 22, 2025 |
| FY2023 | Dec 31, 2022 | ($25.17M) | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | ($22.55M) | Apr 17, 2023 |
| FY2022 | Dec 31, 2020 | ($19.92M) | Apr 18, 2022 |
| FY2020 | Dec 31, 2019 | ($17.26M) | Apr 12, 2021 |
| FY2019 | Dec 31, 2018 | ($14.95M) | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | ($13.68M) | Apr 22, 2019 |
| FY2017 | Dec 31, 2016 | ($12.68M) | Apr 11, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2017 | $62.6K | Apr 22, 2019 |
| FY2017 | Dec 31, 2016 | $24.6K | Apr 11, 2018 |
| FY2016 | Dec 31, 2015 | $5.1K | Apr 11, 2017 |
| FY2015 | Dec 31, 2014 | $12.4K | Apr 18, 2016 |
| FY2014 | Dec 31, 2013 | $578 | Apr 7, 2015 |
| FY2014 | Dec 31, 2012 | $43.9K | Apr 7, 2015 |
| FY2013 | Dec 31, 2011 | $8.8K | Apr 24, 2014 |
| FY2012 | Dec 31, 2010 | $3.1K | Jul 25, 2013 |
| FY2011 | Dec 31, 2009 | $1.0K | Feb 1, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | 0 | Apr 18, 2022 |
| FY2022 | Dec 31, 2020 | 0 | Apr 18, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | 0 | Apr 11, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Apr 11, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Apr 11, 2017 |
| FY2015 | Dec 31, 2014 | 0 | Apr 18, 2016 |
| FY2013 | Dec 31, 2013 | 0 | Apr 24, 2014 |
| FY2013 | Sep 30, 2013 | 0 | Apr 24, 2014 |
| FY2013 | Sep 30, 2012 | 0 | Apr 24, 2014 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10.13B | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | 8.94B | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | 8.31B | Apr 22, 2025 |
| FY2023 | Dec 31, 2022 | 7.17B | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | 6.18B | Apr 17, 2023 |
| FY2022 | Dec 31, 2020 | 5.32B | Apr 18, 2022 |
| FY2020 | Dec 31, 2019 | 4.76B | Apr 12, 2021 |
| FY2019 | Dec 31, 2018 | 3.52B | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | 2.78B | Apr 22, 2019 |
| FY2017 | Dec 31, 2016 | 2.19B | Apr 11, 2018 |